ARK Investment Management LLC Buys 515,399 Shares of CareDx, Inc (NASDAQ:CDNA)

ARK Investment Management LLC grew its stake in CareDx, Inc (NASDAQ:CDNA) by 7.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,194,722 shares of the company’s stock after purchasing an additional 515,399 shares during the quarter. ARK Investment Management LLC owned approximately 0.13% of CareDx worth $86,337,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of CareDx by 24.6% in the second quarter. BlackRock Inc. now owns 5,439,512 shares of the company’s stock valued at $46,236,000 after purchasing an additional 1,074,531 shares during the period. Vanguard Group Inc. raised its position in shares of CareDx by 1.6% in the third quarter. Vanguard Group Inc. now owns 5,065,489 shares of the company’s stock valued at $86,214,000 after purchasing an additional 80,292 shares during the period. State Street Corp increased its position in CareDx by 0.7% during the third quarter. State Street Corp now owns 4,246,025 shares of the company’s stock worth $72,267,000 after acquiring an additional 31,345 shares during the period. Bellevue Group AG increased its position in CareDx by 8.1% during the second quarter. Bellevue Group AG now owns 3,716,477 shares of the company’s stock worth $31,590,000 after acquiring an additional 277,386 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its position in CareDx by 3.0% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,024,503 shares of the company’s stock worth $21,172,000 after acquiring an additional 87,378 shares during the period.

CareDx Stock Performance

NASDAQ:CDNA opened at $10.52 on Thursday. CareDx, Inc has a 52 week low of $4.80 and a 52 week high of $12.93. The firm has a market cap of $544.73 million, a price-to-earnings ratio of -2.97 and a beta of 1.42. The firm’s 50-day simple moving average is $9.66 and its 200 day simple moving average is $8.99.

CareDx (NASDAQ:CDNA) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.97). CareDx had a negative return on equity of 51.40% and a negative net margin of 67.88%. The business had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. During the same period in the prior year, the business posted ($0.34) earnings per share. CareDx’s revenue was down 20.4% compared to the same quarter last year. Sell-side analysts anticipate that CareDx, Inc will post -1.59 EPS for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.